Introduction: Window of opportunity trials in malignant pleural mesothelioma (MPM) are challenging but can yield important translational information about a novel agent.
Methods:
We treated patients with MPM (N ¼ 24) with 4 weeks of oral dasatinib followed by surgery with or without radiotherapy and then an optional 2 years of maintenance dasatinib. The primary end point was biomarker modulation of phosphorylated (p) Src Tyr419 .
Results: For all patients, the median progression-free survival (PFS) was 7.5 months and the median overall survival was 19.1 months. No significant responses were seen after 4 weeks of dasatinib therapy; however, modulation of median p-Src Tyr419 immunohistochemistry (IHC) scores was seen: the median pretreatment score was 70 (interquartile range 37.5-110), and the median posttreatment score was 41 
Introduction
Malignant pleural mesothelioma (MPM) is an orphan disease with few treatment options. In the small proportion of patients who are candidates for aggressive surgical resection, the median survival duration with multimodality therapy remains grim at around 17 months. 1 Recent trials of induction therapy with platinum doublets report higher survival in responders, but these trials were small and not randomized. [1] [2] [3] [4] [5] Nevertheless, they imply that more effective systemic therapies can improve patient survival outcomes; thus, identifying targetable biomarkers predictive for response to systemic agents is critical in this disease.
Src is a non-receptor tyrosine kinase that is associated with tumor cell invasion, proliferation, angiogenesis, and antiapoptosis. [6] [7] [8] Src-associated biological effectors such as metalloproteinases, E-cadherin, and integrin-dependent complexes promote tumor cell invasion, 9 whereas plateletderived growth factor receptor (PDGFR) 8, [10] [11] [12] activates tumor cell proliferation. Src kinase is stimulated by vascular endothelial growth factor receptor 13 and the hypoxia pathway HIF-1a, which increases vascular endothelial growth factor receptor expression. 8, 13 We previously demonstrated that Src kinase is commonly expressed and activated in MPM cell lines and tissue samples by phosphorylation at the activation Src Tyr419 site (phosphorylated [p]-Src Tyr419 ). 14, 15 Our prior immunohistochemistry (IHC) study of 46 surgically resected mesothelioma paraffin-embedded tissue specimens demonstrated that p-Src
Try419 expression was present in 43% of tumor membranes and 67% of tumor cytoplasms. 15 Positive p-Src Tyr419 IHC expression was associated with more advanced disease and greater likelihood of metastatic disease. 15 Dasatinib (BMS-354825, Bristol-Myers Squibb, New York, NY) is a broad-spectrum adenosine triphosphatecompetitive inhibitor of five oncogenic tyrosine kinases/ kinase families (BCR-ABL; SRC; c-Kit; PDGFR, PDGFR alpha [PDGFRA] , and PDGFR beta [PDGFRB] ; and ephrin receptor kinases). Our preclinical studies demonstrated that dasatinib had target specificity to p-Src Tyr419 in mesothelioma cell lines and prevented cell proliferation and invasion. 15 However, dasatinib's mechanism of action may not be limited to Src kinase inhibition, as it may also affect MPM cells and tumors through the PDGF/PDGFR pathway. MPM tumor cells express platelet-derived growth factor (PDGF) and PDGFR [16] [17] [18] [19] [20] [21] [22] and use this pathway as an autocrine loop mechanism for tumor cell proliferation and angiogenesis. [17] [18] [19] [23] [24] [25] We therefore hypothesized that dasatinib would be an effective therapeutic agent in MPM and that the p-Src Tyr419 and PDGF/PDGFR pathway biomarkers would be predictive of clinical outcomes. We sought to test our hypothesis by treating patients with resectable MPM with neoadjuvant dasatinib therapy in a window of opportunity biomarker study. The primary end point was identification of the prognostic and predictive value of p-Src Tyr419 IHC and determination of the extent to which dasatinib modulated the biomarker. Window of opportunity trial assessments in MPM are complexnamely, there are controversial issues of whether MPM surgery (extrapleural pneumonectomy [EPP] or pleurectomy/decortication [P/D]) is beneficial, whether the variable administrations and therapeutic durations of adjuvant novel agents can affect survival, and whether the use of a molecular end point for the primary objective in trials can be valid and translatable to the clinic. However, this trial platform enables a pure assessment of a novel targeted agent and relevant tumor biomarkers.
Methods

Patients, Trial Schema, and Samples
This single-arm institutional review board-approved study (NCT00652574) enrolled patients with potentially resectable (by P/D or EPP) MPM treated at The University of Texas M. D. Anderson Cancer Center between 2008 and 2012. Patient eligibility criteria were age at least 18 years, epithelioid or biphasic histologic type (nonsarcomatoid), resectable disease, no comorbid conditions precluding surgical resection, and chemotherapy-naive status. Patients with untreated MPM underwent extended surgical staging (ESS) 26 with multiple biopsies to account for tumor heterogeneity. Each tumor biopsy specimen removed from the patient was cut in half, with one part flash-frozen and the second part formalin-fixed for paraffin. If deemed surgical candidates for either P/D or EPP, patients received 4 weeks of neoadjuvant dasatinib (70 mg orally twice a day) until the day before surgical resection.
Safety and toxicity were monitored weekly by using the National Cancer Institute Common Toxicity Criteria (version 3.0). The clinical outcomes evaluated were the response rate at 4 weeks by positron emission tomography (PET)/computed tomography (CT) scan, progression-free survival (PFS), and overall survival (OS). PET/CT standardized uptake value (SUV) levels and anatomic tumor measurements by modified Response Evaluation Criteria in Solid Tumors (RECIST) were performed. SUV levels for the primary pleural tumor were utilized for the translational biomarker assessments. If a metabolic or anatomic response on PET/CT scan was seen, an additional 2 years of dasatinib maintenance therapy after adjuvant radiotherapy and chemotherapy was offered.
ESS
As current radiologic imaging cannot accurately rule out the presence of contralateral mediastinal nodal disease or transdiaphragmatic tumor extension (both of which contraindicate resection), we routinely perform ESS on all patients being considered for EPP or P/D. ESS is performed as a single outpatient procedure and includes laparoscopy, mediastinoscopy, bronchoscopy, and video-assisted thoracoscopy or intraoperative ultrasound-guided core biopsy to confirm the histologic diagnosis. 26 ESS is a vital part of the preoperative workup of patients with MPM to rule out advanced-stage disease or sarcomatoid histologic type, which will not benefit from surgical resection.
EPP and P/D
EPP was performed according to methods well described in the literature 27 and according to current practices at The University of Texas M. D. Anderson Cancer Center. Briefly, after appropriate physiologic and oncologic staging, patients underwent thoracotomy and en bloc resection of the affected lung, visceral and parietal pleura, ipsilateral hemidiaphragm, and pericardium. A mediastinal lymph node dissection was also performed. The diaphragm and pericardium were reconstructed with Gore-Tex mesh (W. L. Gore and Associates, Flagstaff, AZ) to prevent intrathoracic herniation of the heart or abdominal viscera. In patients who were found to have extensive disease at the time of thoracotomy that was not identified preoperatively (such as multifocal chest wall involvement), exploratory thoracotomy or pleurectomy was performed rather than pneumonectomy. Additionally, patients who were symptomatic from disease burden and who had limited pulmonary reserve were allowed to undergo P/D rather than EPP. P/D was performed in a manner similar to EPP; however, the lung was left in situ and the tumor peeled off the surface of the lung and chest wall. P/D is considered a less complete cytoreduction than EPP and is generally performed only as a palliative procedure. However, in a large case study, P/D was reported to have superior survival outcomes compared with EPP. 28 
Statistical Analysis
Primary End Point Evaluation. Analysis of p-Src Tyr419 and PDGFR pathway biomarkers was performed by standard IHC procedures detailed in prior publications. 15 Briefly, unstained slides were used for IHC analysis of pSrc Tyr419 and PDGFR pathway biomarkers. A weighted staining score was used to measure the extent of kinase and receptor phosphorylation. This score, which ranges from 0 to 300, is semiquantitative and considers both the intensity and percent positive expression. For example, a weighted staining score of 100 reflects 100% of cells staining 1þ or 50% of cells staining 2þ. The maximum score of 300 represents a case in which 100% of the cells stain 3þ. 15, 29, 30 Exploratory analyses included clinical outcome correlation of the following tumor biomarkers in the cytoplasm, stroma, and nucleus: PDGFRA, PDGFRB, p-PDGFRA, and p-PDGFRB. Platelet-derived growth factor receptor beta gene (PDGFRB) gene copy number gain by fluorescent in situ hybridization (FISH) positivity was defined by two cutoffs (i.e., any number of cells among 50 cells with PDGFRB gene copy number gain using the cutoffs of 3 or 4 copies).
Clinical Statistical Analysis. The primary end point of this study was modulation of p-Src Tyr419 IHC expression. On the basis of our preclinical studies, 15 we assumed that 67% of the subjects would have positive p-Src Tyr419 expression in the tumor cytoplasm and that, after dasatinib therapy, the percentage of subjects with positive p-Src Tyr419 expression would be reduced to 33% (i.e., an approximately 50% relative reduction chosen on the basis of preclinical murine data). 31 These assumptions correspond to the following proportions of subjects showing a difference between pre-p-Src Tyr419 expression before and after dasatinib treatment. A total of 21 patients were required to achieve 80% power with a one-sided 10% type 1 error rate (computation provided by nQuery Advisor, version 6.01). To account for a 10% inevaluable rate, the target sample size was 24. With 21 patients, we could detect an effect size (treatment difference divided by the standard deviation) of 0.643 with 80% power and a two-sided 5% type I error rate. The Wilcoxon signed-rank test and signed test were applied whenever appropriate. The McNemar test was applied for binary data. In addition, we analyzed p-Src Tyr419 IHC expression as a continuous variable and as single maximum data points. The magnitude of biomarker modulation was tested and quantified by a paired t-test and Wilcoxon signed-rank test. For continuous data, the paired t-test was used for testing the biomarker modulation before and after treatment.
To ensure patient safety on this trial, we incorporated an early stopping rule into our statistical design. Our institution's 30-day mortality rate after EPP as a single modality is 8% 32 ; we would have halted the study if the probability of the 30-day mortality rate after EPP being greater than 16% had been high (>70%). The early stopping rule was applied after the first 6 patients were treated. The trial would have been terminated early if the ratio of number of deaths to number of patients was higher than 2/ 7, 3/12, 4/17, or 5/23. If the true mortality rate is 8%, 16%, and 24%, the probability of early stopping is 13.5%, 45.8%, and 75.8%, respectively. The toxicity early stopping rule was derived under the beta-binomial model assuming a vague prior of beta (0.08, 0.92). The calculation was performed with S-PLUS software.
Tissue Biomarker Analysis. In the exploratory analysis, the tumor tissue IHC biomarkers and correlation with clinical outcomes were evaluated by three main methods. First, the baseline biomarkers were evaluated and correlated with survival and tumor radiologic and pathologic response. This was assessed first by averaging the IHC biomarker scores from the multiple biopsy specimens taken from different areas of the tumor at baseline and after neoadjuvant therapy. Second, clinical outcomes were correlated with the change in paired IHC scores between the averaged baseline and posttreatment IHC scores. Within each of the two methods of IHC evaluation, the IHC scores were assessed using (1) a median cutoff (higher than the median versus lower than or equal to the median), (2) continuous values, or (3) positive expression versus no expression.
The chi-square test or Fisher's exact test was used to test differences between categorical variables, and the Wilcoxon rank sum test or Kruskal-Wallis test was used to detect differences in continuous variables between groups. 33 The Spearman correlation coefficient (rho) was used to assess the correlations between age and the baseline markers and the correlations between the markers at baseline. 33 The distributions of OS and PFS were estimated by the Kaplan-Meier method. 34 The logrank test 35 was performed to test the difference in survival between groups. Regression analyses of survival data based on the Cox proportional hazards model 35 were conducted for OS as well as for PFS. When the baseline markers were assessed for their associations with OS or PFS, OS was defined as the time from the start of dasatinib treatment to death or last contact. PFS was defined as the time from the start of dasatinib treatment to progression, death, or last contact. When the modulations of the markers were assessed for their associations with OS or PFS, OS was defined as the time from the time of surgery to death or last contact. PFS was defined as the time from the time of surgery to progression, death or last contact. SAS, version 9.2, and S-Plus, version 8.04, were used to carry out the computations for all analyses.
RPPA Analysis. Reverse phase protein array (RPPA) slides were printed from lysates, and RPPA studies were performed as described previously (the details are include in the Supplementary Methods).
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Results
Window of Opportunity Biomarker-Driven Trial Is Feasible in Resectable MPM
A total of 56 patients with potentially resectable MPM (by P/D or EPP) were screened from 2008 to 2012, and 28 were found to have nonresectable tumors on baseline diagnostic imaging or by ESS. Of the 28 patients enrolled onto this single-arm trial of neoadjuvant dasatinib for 4 weeks until the day before surgical resection, 24 were evaluable for biomarker results, as two patients missed several dasatinib doses and two patients withdrew consent.
The patient demographics were typical for patients with MPM (Table 1 ). The main side effects attributed to neoadjuvant dasatinib were grade 1 to 2 fatigue, anorexia, nausea, and edema. The median follow-up for all patients was 19 months, with a median PFS 7.5 months (95% confidence interval [CI]: 2.1-15.5) and OS 19.1 months (95% CI: 11.5-24.1). Two patients died within 30 days of surgery, one from a pulmonary embolus and one from pneumonia. The 1-and 2-year PFS rates were 33% (95% CI: 19%-59%) and 14% (95% CI: 5%-43%). The 1-year, 2-year, and 3-year OS rates were 71% (95% CI: 55%-92%), 35% (95% CI: 20%-62%), and 15% (95% CI: 5%-42%), respectively. For the eight patients who underwent EPP, the median PFS was 8.3 months (95% CI: 1.87-27.27) and the median OS was 24 months (95% CI: 1.87-48.03). For the 13 patients who underwent P/D, the median PFS was 7.5 months (95% CI: 2.07-18.53) and the median OS 21 was months (95% CI: 9.79-29.77). Three patients had multiple areas of chest wall invasion that were not identified before resection and aborted surgery; their median PFS was 0.9 months (95% CI: 0.85-0.92) and their median OS was 12.8 months (95% CI: 12.62-12.92).
If a decrease in SUV levels or anatomic response on PET/CT scan was seen, an additional 2 years of dasatinib maintenance therapy after resection and adjuvant therapy was offered. Only four of 17 eligible patients consented to proceed with maintenance dasatinib. Two of these patients subsequently withdrew consent after a few days because of grade 3 fatigue, grade 3 malaise, and grade 2 nausea. The remaining two patients (both had P/D) received adjuvant maintenance dasatinib (Fig. 1A and B) . One patient stopped taking dasatinib at 18.5 months owing to grade 2 fatigue, grade 2 weight loss, and grade 1 nausea and immediately had disease recurrence. The other patient took dasatinib for 2 years and remained disease-free for 31.5 months.
In the patients who experienced recurrence after multimodality therapy, OS was affected by subsequent therapies. Patients who received posttrial systemic therapy (n ¼ 14) had a median OS of 23.4 months (95% CI: 12.6-30) compared with 9.7 months (95% CI: 1.9-21) for those who did not (n ¼ 10). The median OS increased with each subsequent line of therapy; those who had received one line of prior therapy (n ¼ 10) had a median OS of 20 months (95% CI: 11.1-29.8), whereas those who received two or more lines of therapy (n ¼ 4) had a median OS of 37.9 months (95% CI: 12.7-54.1).
p-Src Tyr419 Levels and Clinical Outcome
p-Src Tyr419 IHC levels were analyzed in baseline MPM tissue specimens from multiple biopsies performed as part of ESS and in resection specimens after 4 weeks of dasatinib treatment (Fig. 1B) . IHC scores from the multiple biopsy specimens were averaged as part of this Tyr419 immunohistochemistry (IHC) expression (positive staining is seen as brown staining) before (ii and vi) and after (iv and viii) neoadjuvant dasatinib therapy. The pretreatment photos (ii and vi) show strong membrane p-Src Tyr419 expression at baseline, whereas after neoadjuvant dasatinib, the tumor p-Src Tyr419 IHC expression markedly diminishes (iv and viii), reflecting positive modulation of IHC p-Src Tyr419 by dasatinib therapy. Both patients with a decrease in standardized uptake value levels had significant downregulation of p-Src Tyr419 after neoadjuvant dasatinib treatment.
analysis. Supplementary Figure 1 (Fig. 2B) .
Patients who had a decrease in p-Src Tyr419 IHC levels after neoadjuvant dasatinib treatment had a longer median PFS (6.9 months versus 0.94 months [p ¼ 0.03]) compared with patients who had rising p-Src Tyr419 levels ( Fig. 3A and B (Fig. 4A and B) . Patients who had a decrease in SUV levels at 4 weeks had decreasing cytoplasmic PDGFRA levels (p ¼ 0.02) from baseline.
Baseline higher-than-median IHC expression of PDGFRB in the cytoplasm (HR ¼ 2.54, 95% CI: 1-6.41, p ¼ 0.048), stroma (HR ¼2.79, 95% CI: 1.1-7.07, p ¼ 0.03), and nucleus (HR ¼ 6.79, 95% CI: 1.31-35.33, p ¼ 0.023) correlated with a worse PFS (Fig. 4C and D) . In the patients who underwent surgical resection, higher stromal p-PDGFRB expression correlated with worse PFS (HR ¼ 3.26, 95% CI: 1.0-10.62, p ¼ 0.05) (Fig. 4E ). There were no significant correlations between OS and the PDGFR biomarkers. However, a trend toward longer OS with any cytoplasmic PDGFRA expression (HR ¼ 0.4, p ¼ 0.08) and a trend toward shorter OS with higherthan-median stromal PDGFRB expression (HR ¼ 2.26, p ¼ 0.07) were seen.
Higher PDGFRB Gene Copy Number Gain by FISH Associated with Lack of Response to Dasatinib
Analysis of PDGFRB copy number gain using FISH revealed 19 patients who were PDGFRB FISH-positive at baseline (17 patients with at least three copies and two with at least four copies). The presence of any PDGFRB FISH positivity correlated with a lack of response to dasatinib neoadjuvant therapy. PDGFRB FISH-negative patients were more likely to have a decrease in SUV levels on PET/CT scan compared with PDGFRB FISHpositive patients (60% versus 11.8% [p ¼ 0.05]). There was a significant decrease in PDGFRB FISH positivity after dasatinib therapy (p < 0.0001). However, this change was not associated with response, PFS, or OS. In fact, patients who had a reduction in SUV at 4 weeks were more likely to have no change in PDGFRB FISH status (p ¼ 0.04). PDGFRB FISH positivity did not correlate with any increase in PDGFRB IHC levels at any cell-localized site. However, PDGFRB FISH positivity with at least three copies negatively correlated with stromal PDGFRA levels (rho ¼ -0.505, p ¼ 0.01).
RPPA Analysis
RPPA analysis demonstrated significant differences between before dasatinib therapy and afterward, especially in p-Src 527 (p > 0.99). However, none of the markers were predictive or prognostic for response or survival outcomes. Also, the difference in modulation between the markers was also not predictive or prognostic for clinical outcomes.
Discussion
We have successfully shown that this neoadjuvant window of opportunity trial with a biomarker-based primary end point with multiple paired tissue biopsy specimens in resectable MPM is a safe and feasible infrastructure for conducting translational research in MPM. We continued dasatinib treatment until the day before surgery without any delays of the surgical resection or added toxicity beyond the historical control. This was necessary for the biomarker analysis, as several preclinical and phase I studies have shown that the effects of dasatinib remain prevalent within the tumor and peripheral blood mononuclear cells for only 24 hours after the last dose of treatment. 31, 40 In our trial, our PFS and OS results were similar to those described in the literature from other trimodality studies. 1, 41 Of note, our patients who underwent EPP had survival outcomes similar to those of our patients who underwent P/D, although this result may have been affected by the number of subsequent poststudy therapies that the patients received. In light of the MARS 42 analysis and a prior retrospective study suggesting equivalent surgical benefit for P/D and EPP, 28 our small data set supports the role of P/D in extending PFS and OS in a manner similar to that of EPP. In addition, we had two patients undergoing P/D who received adjuvant maintenance dasatinib and remained disease-free for the duration of treatment (18.5 and 31.5 months) but progressed upon cessation of dasatinib. Although we are unable to validate that adjuvant consolidation dasatinib improves survival outcomes, the experience of these two patients suggests that PFS can be improved after resection with an appropriate maintenance targeted therapy. Further investigations with a larger number of patients will also be needed to evaluate this concept of adjuvant consolidation targeted therapy providing PFS benefit.
Our study does have significant limitations in the biomarker interpretation, some of which are intrinsic to the nature of window of opportunity studies. 43 First, the numbers of patients with MPM treated on this study is small, which limits interpretation of the results. Second, to avoid delaying surgical resection, the dasatinib was given for short period of time (4 weeks) and dasatinib does not have a large treatment effect in MPM. Thus, correlations with RECIST/modified RECIST radiologic responses were not feasible and an alternative end point other than radiographic response was needed to assess the pharmacodynamics of the translational biomarkers. PET/CT SUV levels of the primary pleural tumor were therefore chosen for the correlation, which is not a validated measurement system for survival and has the potential confounding factor of false elevation because of prior talc pleurodesis or inflammation. At the time this study was performed, the technology for volumetric CT scans and magnetic resonance imaging studies were not available. Lastly, although this trial did offer maintenance adjuvant dasatinib therapy in patients who demonstrated a decrease in PET/CT SUV levels, most eligible patients declined this option on account of treatment fatigue. As such, the impact of dasatinib and correlation of biomarkers with survival outcomes is limited. With these limitations in mind, our tumor biomarker analysis suggests that p-Src Tyr419 may be a reasonable pharmacodynamic biomarker for dasatinib therapy and that 4 weeks of treatment was sufficient to see tumor biomarker modulation. The higher magnitude of downregulation of posttreatment p-Src Tyr419 levels correlated with a greater reduction in SUV levels and prolonged PFS. In addition distinct PDGFR biomarker phenotypes at baseline had predictive value for dasatinib; patients with low cytoplasmic p-PDGFRA and negative PDGFRB (by FISH) had lower SUV levels, whereas patients with an increase in SUV levels had high PDGFRB in the nucleus and cytoplasm and positive PDGFRB by FISH. Patients with higher PDGFRB expression (cytoplasm, stroma, and nucleus) had a worse PFS, which is consistent with the dasatinib-resistant phenotype.
It is plausible that high overexpression of PDGFRB is a mechanism of resistance that overcomes the dasatinib tyrosine kinase inhibition. PDGFRB is known to be important in development of vascular support cells in the microenvironment 44 and may have a role in the activation of epithelial-mesenchymal transition. 45 Also, in our patients who underwent resection, a shorter PFS was associated with higher baseline p-PDGFRB expression in the stroma. The presence of phosphorylation on PDGFRB indicates ligand binding and autophosphorylation of the receptors on tyrosine residues, which subsequently enact signal transduction. This implies that stimulation of the stromal PDGF/PDGFRB pathway promotes tumorigenesis in MPM and is hypothesis generating in that high stromal p-PDGFRB levels could potentially be used to identify patients with MPM who have more aggressive disease.
Our analysis shows that the PDGFR pathway may be an important therapeutic target in mesothelioma. PDGFRA and PDGFRB emerged as potential prognostic markers with higher cytoplasmic PDGFRA expression associating with a trend toward improved OS and higher PDGFRB expression correlating with a worse PFS. We had two long-term survivors (one of whom underwent EPP and one of whom underwent P/D) whose biomarker profiles were distinct from those of other patients; both patients had a high cytoplasmic PDGFRA expression (35 versus 4.29 [p ¼ 0.036]) and lower median stromal PDGFRB expression (5 versus 50, [p ¼ 0.016]). These preliminary findings support the need for additional research into the PDGFR pathway in MPM. This is highly relevant at this time, as certain vascular endothelial growth factor receptor/PDGFR tyrosine kinase inhibitors have shown preliminary efficacy in the frontline metastatic setting with chemotherapy. 46, 47 In conclusion, there was no significant efficacy signal with dasatinib, and dasatinib monotherapy is unlikely to continue to be studied in MPM. The PDGFR pathway and receptor subtypes may be important to target therapeutically in this disease, as they may have a role in prognosis and also in resistance to antiangiogenic tyrosine kinase inhibitors. Future efforts should continue to use the neoadjuvant trial framework as a vehicle for translational research and should also include endeavors to develop surrogate predictive biomarkers in peripheral blood and address intratumor heterogeneity for both protein expression and genetic sequencing.
